Soumya Patil

Soumya Patil

Auto-generated profile, based on publicly available information

Soumya Patil

Department of Pharmacy Practice, NGSM Institute of Pharmaceutical Sciences (NGSMIPS), Nitte (Deemed to be University), Mangalore, Karnataka, India

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 August 2025 in Biomarkers
Verified
Journal Article
Closed access
SPSoumya Patil
Soumya Patil
Raushan Kumar ChaudharyRaushan Kumar Chaudhary
Raushan Kumar Chaudhary
PPPrakash Patil
Prakash Patil
PSPraveenkumar Shetty
Praveenkumar Shetty
VSVijith Vittal Shetty
Vijith Vittal Shetty
UMUday Venkat Mateti
Uday Venkat Mateti
Actin-like protein 6A (ACTL6A), a subunit of SWI/SNF (SWItch/Sucrose Non-Fermentable) complex has emerged as a key player in cancer progression. Despite growing evidence of its oncogenic potential, a comprehensive evaluation of its role in tumorigenesis and clinical outcomes remains warranted. This systematic review and meta-analysis aim to elucidate the role of ACTL6A in cancer pathophysiology and its prognostic significance. A systematic search in PubMed, Scopus, and Web of Science was conducted from inception to 31st December 2024, using the keywords "ACTL6A" and "Cancer." Studies investigating ACTL6A's role in cancer and those reporting hazard ratios for ACTL6A expression in human samples were considered for systematic review and meta-analysis, respectively. A total of 39 studies were included in systematic review which collectively reported the role of ACTL6A in tumorigenesis, invasion, and metastasis via HIPPO-YAP, PI3K/AKT, NOTCH and Wnt/β-catenin pathways. Six studies (n = 863) qualified for meta-analysis, revealing that ACTL6A overexpression was significantly associated with poor overall survival (OS) (p = 0.001), larger tumor size (p < 0.01) and higher tumor grade (p = 0.002). ACTL6A is a critical oncogenic driver which promotes cancer progression and poor clinical outcomes. ACTL6A may serve as a promising prognostic marker, paving the way for targeted therapeutic strategies in oncology.

24 July 2023 in Future Journal of Pharmaceutical Sciences
Verified
Journal Article
Open access
PDF file
DADeepthi Avvaru
Deepthi Avvaru
SPSoumya Patil
Soumya Patil
BDBhavana Doshi
Bhavana Doshi
SWShashikala Wali
Shashikala Wali
Background: Nicolau syndrome is a rare adverse drug reaction clinically presented with painful erythema and tissue necrosis often accompanied by intramuscular injections of NSAIDS (diclofenac), penicillin, corticosteroids and local anesthetics. Case presentation: This case report describes a 29-year-old male patient who was repeatedly hospitalized for the treatment of recalcitrant pemphigus vulgaris. When the patient visited for the fourth time to our hospital, he complained of unusual sharp pain over the right gluteal region ever since the administration of diclofenac 75 mg intramuscular injection for persistent back pain during his previous stay. On physical examination, the right gluteal region showed a globular swelling with erythema and pus filled necrosed tissue. The CT scan did not show any presence of hematoma, ruling out any possibility of compartment syndrome. Based on this clinical evidence he was diagnosed with Nicolau Syndrome secondary to diclofenac injection. The tissue injury necessitated surgical debridement and after a span of 2 months, it healed leaving a permanent scar. In addition, this case report highlights the treatment of recalcitrant pemphigus vulgaris with rituximab therapy. Conclusion: Clinical pharmacist plays a vital role in educating healthcare professionals about following right protocol for administration of injectable drugs, early detection and management of the ADR. Similarly, patient receiving injections should be educated about warning signs and symptoms of such adverse drug reaction.

1 November 2024 in Current Drug Safety
Verified
Journal Article
Closed access
PDF file
SPSoumya Patil
Soumya Patil
MPMAHANTESH PATIL
MAHANTESH PATIL
ABApoorva Bagalkotkar
Apoorva Bagalkotkar
SWShashikala Wali
Shashikala Wali
Background: Primary membranous nephropathy is a rare presentation in children. Patients unresponsive to steroids and experiencing frequent relapse are considered steroid-resistant. They often require complex treatment regimens consisting of immunosuppressants like cyclophosphamide, tacrolimus, and cyclosporin A. Case: In the present case, a 5-year-old child was suffering from steroid-resistant nephrotic syndrome for the past 10 months. He was initially treated with prednisolone 20mg but was subsequently found to be steroid-resistant. A renal biopsy revealed primary podocytopathy with immunocomplex deposits in podocyte tissues, suggesting primary membranous nephropathy as the cause of SRNS (steroid-resistant nephrotic syndrome). Cyclophosphamide 25mg twice daily was added to the treatment plan since the child did not tolerate tacrolimus therapy. During a subsequent follow-up, the physician reduced the cyclophosphamide 25mg dose to once a day, but parents misinterpreted this, and the child received a larger dose, cyclophosphamide 25mg, four times a day for 20 days. This resulted in cyclophosphamide toxicity-induced neutropenia, alopecia and posing the child at greater risk of sepsis. Conclusion: Nephrotic syndrome is a chronic disease that demands extensive treatment plans and strict monitoring. Medication errors are common among parents or caregivers of pediatric patients. This case is a take-home message emphasizing the significance of patient-centered communication in preventing medication errors. A clinical pharmacist can aid in conveying simple and unambiguous information to parents or caregivers.

11 February 2026 in Journal of Oncology Pharmacy Practice
Verified
Journal Article
Closed access
APAllen Pinto
Allen Pinto
RRRajesh Raju
Rajesh Raju
SPSoumya Patil
Soumya Patil
NVNazah Naurah V
Nazah Naurah V
Raushan Kumar ChaudharyRaushan Kumar Chaudhary
Raushan Kumar Chaudhary
Objective: To study the cumulative proportion of favorable response to Histone Deacetylase Inhibitor (HDACi) among head and neck cancer (HNC) patients. Data Sources: A systematic search (till 17 th -May-2025) was carried out in PubMed, Scopus, and Web of Science databases using “Head and Neck cancer” and “HDAC inhibitors” as key concept where all the single-arm clinical trials which have clear data on response to HDACi therapy-based RECIST criteria among HNC patients were included in this study. The meta-analysis was performed using R software. Data Summary: The search resulted in a total of 178 articles, of which 7 studies were found to be relevant based on the inclusion criteria. Out of a total of 101 advanced HNC patients treated with HDACi in single-arm clinical trials, 74 patients showed favorable antitumor response. The pooled cumulative proportion of favorable response with the random effect model was found to be 0.65. Out of these 7 studies, the average proportion of antitumor response was calculated to be 0.758 among HNC patients who received HDACi concurrently with chemotherapy, chemoradiotherapy, and targeted therapy, whereas the average proportion of antitumor response rate to HDACi was 0.485 among priorly treated HNC patients. Vorinostat was the most used HDACi, where the proportion of favorable response was 0.49 compared to the non-vorinostat HDACi (0.77), like valproic acid, panobinostat, and romidepsin. Conclusion: The overall antitumor response to HDACi was found to be 0.65 (65%), which supports the use of HDACi among advanced HNC patients, particularly along with the concurrent chemo/chemoradiotherapy or targeted therapy.

3 July 2026 in Journal of Applied Pharmaceutical Science
Verified
Journal Article
Open access
AAAmna Reem M. A.
Amna Reem M. A.
SPSoumya Patil
Soumya Patil
AKAdithi Kellarai
Adithi Kellarai
UMUday Venkat Mateti
Uday Venkat Mateti
Diabetic distress remains underreported, with its incidence and prevalence varying across regions and lacking consistent documentation. Furthermore, routine clinical practice rarely incorporates standardized assessment of this form of distress. Therefore, we aimed to translate, validate, and test the reliability of the Problem Areas in Diabetes (PAID)-20 scale into two regional languages, Malayalam and Kannada, and evaluate the diabetes-associated distress and its association with glycaemic control and sociodemographic factors among patients with type 2 diabetes mellitus (DM). Following validation, both the scales were administered to assess distress scores and their association with patients’ sociodemographic and clinical parameters. Further, the validated scales were found to be reliable for their regional use (Cronbach- α > 0.7). A cross-sectional study was conducted among 354 patients with type 2 DM at a tertiary care hospital; males (63.84%) were predominant over females (36.16%), with the overall mean age of 61.1 ± 10.25 years. The prevalence of diabetes-related distress was 28.8%, with a weak positive correlation between glycated hemoglobin (HbA1c) levels and diabetes-related distress, which was statistically significant ( r = 0.141, p = .008), indicating that poorer glycemic control is associated with higher distress. Further, family history of diabetes and socioeconomic status were found to have a marginally significant association with distress level among diabetes patients ( p = .059 and p = .055). Routine assessment of diabetes distress using these regionally adapted tools may facilitate clinical and psychological diabetes management.